Clinical Trial: Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07663747) titled 'Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC' on April 28.

Brief Summary: This is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach

Study Start Date: Sept. 01, 2026

Study Type: INTERVENTIONAL

Condition: Urothelial Bladder Cancer

Intervention: DRUG: Enfortumab Vedotin

Induction: 4 cycles (d1,8; 1.25 mg/kg)

DRUG: Pembrolizumab

Induction: 4 cycles 200mg and after cCR 400 mg q6 weeks. Total 1 year from start of therapy

RADIATION: Radiation

The preference will be a four...